Although full PPARγ agonists, such as TZDs, improve insulin sensitivity and reduce blood glucose levels 21, 22, their clinical utility is restricted by side‐effects, including weight gain, fluid retention and increased risk of congestive heart failure 23, 24, 25. The gene discussed is PPARG; the disease is congestive heart failure.